跳至主要内容
临床试验/NCT01828931
NCT01828931已完成不适用

Effectiveness of Intensive Lifestyle Interventions in the Management of Diabetes in Individuals With Psychosis

Centre for Addiction and Mental Health2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
120
试验地点
2
主要终点
HbA1c levels

研究概览

简要总结

The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population. Life expectancy of individuals with psychosis is also 20-25 years less than the general population, primarily due to premature onset of cardiovascular disease (CVD). Despite the high risk for T2DM and CVD, psychotic illness has been an exclusion criterion in all large-scale studies of diabetes prevention and management. We propose a 3-year randomized controlled trial examining the effectiveness of a lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity in overweight or obese individuals (N=150) suffering from both a psychotic illness and T2DM. Weight and glycemic control will be the primary outcome variables. It is hypothesized that a significant weight reduction and improvement in glycemic control will be found in those who receive the LI relative to those who do not.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Between the ages of 18 and 70 years (inclusive)
  • DSM-IV-TR diagnosis of one of the psychotic disorders listed above
  • Body Mass Index (BMI) > 25 kg/m2 at the time of enrollment
  • Clearly documented diagnosis of type-2 diabetes mellitus or prediabetes
  • Ability to provide informed consent
  • No medical contraindication to participation in weight reduction / exercise program, determined in consultation with their primary care physician
  • Female participants, of childbearing potential, using a medically accepted means of contraception

排除标准

  • Inability to give informed consent
  • Currently enrolled in a formal structured weight management program
  • Currently being prescribed medication specifically for weight loss
  • Participants with unstable or active cardiovascular illnesses (myocardial infarction, CHF, etc), active or end-stage renal disease, unstable thyroid disease, etc.
  • Recurrent episodes of diabetic ketoacidosis, seizure or coma without warning or severe hypoglycemia

结局指标

主要结局

HbA1c levels

时间窗: 52 weeks

Weight

时间窗: 52 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Margaret Hahn

Staff Psychiatrist

Centre for Addiction and Mental Health

研究点 (2)

Loading locations...

相似试验